Piper Sandler on TransMedics Group (TMDX): 'Assessing the $2.2B U.S. Kidney Opportunity'
Tweet Send to a Friend
Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $120.00 price target on TransMedics Group (NASDAQ: TMDX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
